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Survey of Third-Party Parenting Options
Associated With Fertility Preservation
Available to Patients With Cancer Around
the Globe
abstract
Purpose In the accompanying article, “Analysis of Fertility Preservation Options Available to Patients With
Cancer Around the Globe,” we showed that specific fertility preservation services may not be offered at
various sites around the world because of cultural and legal barriers. We assessed global and regional
experiences as well as the legal status of third-party reproduction and adoption to serve as a compre-
hensive international data set and resource for groups that wish to begin oncofertility interventions.
Methods We provide data on the legalities of third-party assisted reproductive technologies and other
family-building options in the 28 oncofertility-practicing countries surveyed.
Results We found regional and country differences that will be important in the development of tailored
resources for physicians and for patient brochures that are sensitive to these local restrictions and cultural
norms.
Conclusion Because many patients first consult Web-based materials, the formal assessment of the
availability of these options providesmembers of the global oncofertility communitywith data towhich they
might otherwise not have ready access to better serve their patients.
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INTRODUCTION
Fertility management in the cancer setting (ie,
oncofertility) is challenging for a variety of techni-
cal reasons that are associated with timing of
cancer treatment, the invasive nature of some
options, and the required links between cancer
and fertility care.1 In addition to these practice
management and biologic hurdles, we identified
the legal status of adoption and third-party re-
production as a barrier. We then assessed the
specific roadblocks that exist in surveyed coun-
tries. The goal of this analysis is to deliver author-
itative information to emerging practices that may
receive information about the field froma variety of
Web resources and that may be unaware of local
barriers to the spectrum of options.
METHODS
The survey design, data collection, and analysis
are described in the accompanying article.1 Sur-
vey respondents were asked about barriers to
counseling patients on and providing them with
all existingparentingoptions in the faceof acancer
diagnosis, gonadotoxic treatment, and possible
consequent infertility. Answers provided specifics
on challenges faced at their center and/or within
their country, which motivated us to conduct addi-
tional research and present detailed data about the
legality of surrogacy; adoption; and egg, sperm, and
embryo donation.We listed the information in tables
andconducteda literature search to fill in the gaps in
the original data and to validate the information
provided. All authors approved the information pre-
sented in the Data Supplement.
RESULTS
A significant barrier to oncofertility care noted in
the survey responses1 was the presence of legal,
cultural, and regulatory restrictions. Adoption and
third-party assisted reproductive technology
(ART), including surrogacy and egg, sperm, and
embryo donation, were consistently identified as
associated with these restrictions. We assessed
the prevailing laws in each country with regard to
surrogacy; adoption; and egg, sperm, and embryo
donation (Data Supplement).
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Surrogacy (Gestational)
Of the 28 countries surveyed, altruistic surrogacy
is explicitly legal in 12, whereas nine outlaw it.
Specific restrictions apply to whom may access
surrogacy in six countries, whereas in six other
countries, all people may access it no matter their
sexual orientation or marital status. Surrogacy is
unregulated by law in 19 countries (Data Supple-
ment), and altruistic surrogacy arrangements oc-
cur in nine of these countries without regulation.
Commercial surrogacy is explicitly prohibited in11
countries. In Iran, for example, both altruistic and
commercial surrogacy are practiced, but no reg-
ulation of these arrangements exists. In theUnited
Kingdom and Australia, advertisement for surro-
gacy is illegal, which is also true in Canada where
brokers and advertisement are illegal. In four
countries, surrogacy is accessible to both citizens
and foreigners (Iran, Belgium, Russia, and Can-
ada). The laws that govern the practice of surro-
gacy greatly differ among states in Mexico, the
United States, and Australia.
Adoption
In almost all countries surveyed, adoption is ex-
plicitly legal, except in Egypt, where it is prohibited
(Data Supplement). In six of these countries, leg-
islation allows homosexual married couples to
adopt. In other countries, such as Chile, adoption
for homosexual couples is illegal; however, be-
cause single persons may adopt, homosexual
couples may apply, but only one person is recog-
nized as the legal parent. In India, Iran, Turkey,
Denmark, Portugal, the Netherlands, and Argen-
tina, couples (either heterosexual or homosexual)
must have lived together for a certain number of
years at the time of adoption. In four countries,
adoption is only available to heterosexual married
couples. In some countries, adoption is highly
restricted; in Iran, for example, neither person
in a couplewho seeks to adopt canhave a chronic,
contagious, or terminal disease.
Egg, Sperm, and Embryo Donation
Egg donation is legal in 19 of the 28 countries
surveyed (Data Supplement). In four countries,
egg donation is illegal, and in five countries, it is
unregulated. In a majority of countries (n = 22),
eggdonation is accessible toheterosexualmarried
couples. In 12 countries, it is also accessible to
homosexualmarried couples, and in 17countries,
it is accessible to unmarried persons.
Similar results are reported for sperm donation,
which is legal in 20 of the countries surveyed,
illegal in three, and unregulated in five. Sperm
donation is accessible to heterosexual married
couples in 23 countries, to homosexual married
couples in 12, and to unmarried couples in 18. In
some countries, such as Iran, sperm donation is
only available whenmedically necessary (in cases
of infertility).
Embryo donation is explicitly legal in 13 countries
surveyed but is illegal in nine and unregulated in
six. Embryo donation is accessible to heterosexual
couples in 17 countries, to homosexual married
couples in seven, and to unmarried couples in 12.
In 10 countries, anonymous gamete or embryo
donation is permitted. In South Korea, embryo
donation is only permitted for research purposes,
and such research studies must be approved by
the institutional reviewboard and related to certain
disease categories, such as infertility, contracep-
tion, and certain rare or incurable diseases. In
BelgiumandDenmark,both anonymousandnon-
anonymous donations of gametes and embryos
are legal, but nonanonymous embryo donation is
illegal in Belgium.
DISCUSSION
The survey responses indicated various legal chal-
lenges about specific procedures. One notable
cultural and legal barrier to oncofertility care was
related to the use of surrogacy. The survey findings
agree with those reported in a study by Wennberg
et al2 in Sweden in which women’s attitudes toward
ARTs were neutral or favorable, except for surro-
gacy. In addition, we found significant hurdles to
third-party procedures, such as age restrictions and
requirements of medical indications to allow treat-
ment, which also proves consistent with previous
studies.3 These data highlight the importance of
more-explicit investigations into these questions,
particularly their sociologic etiologies, legal implica-
tions, and variations among world countries and
regions.
During the development of the survey ques-
tions, we believed it crucial to ask about third-
party ARTs, namely surrogacy and adoption,
along with egg, sperm, and embryo donation.4,5
The rationale for including surrogacy early in the
initial fertility consultation is that women who are
sterile as a result of cancer may also have uterine
dysfunction and a higher risk of recurrent mis-
carriage.4-7 Thus, providers should consider a con-
versation with patients about their ability to carry
offspring after cancer treatment, including the pos-
sibility that third-party alternatives might be neces-
sary in the setting of uterine dysfunction.4,7 The
mention of surrogacy and adoption options
provides patients with full knowledge of all
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possibilities that they may pursue after treatment,
regardless of their remaining fertility function.6 For
patients who did not preserve fertility before treat-
ment,adoption isanotheroption for familybuilding.
India is a prime example of the potential negative
impact of regional differences in laws and social
restrictions with regard to surrogacy, particularly
with surrogacy tourism. Before commercial sur-
rogacy was banned countrywide for foreigners in
2016,8 profits often were collected by middle
men and agencies rather than by the women
who worked as surrogates,9 which supports the
argument for a standard set of policies to favor
altruistic surrogacy and adoption and to prevent
exploitation of surrogates. Such a policy might be
recommended by global health organizations,
such as the WHO. In addition, surrogacy customs
and laws should be made comprehensive, easily
interpretable, and translational to avoid exploitive
surrogacy tourism in poorer communities where
womenmay be willing to compromise their beliefs
andhealth formonetarygainor arepressured todo
so by others.9,10
Adoption is another service the survey identified to
be associated with cultural and legal barriers. At
first glance, adoption is legal inmost countries, but
couples do not often pursue it, as indicated in the
open-ended survey responses. The Hague Adop-
tion Convention, an international agreement that
established the ethics and proper practices for
intercountry adoption, has been upheld by 98
countries since its founding in 1993.11 This
agreement provides the legal precedent for pro-
viders to begin the conversation with young pa-
tients or families. A similar convention was
recently convened by the Hague Conference on
Private International Law on the private interna-
tional legal issues that surround the status of
children, including issues that arise from interna-
tional surrogacy arrangements. This meeting
established that contemporary global standards
should be developed to avoid the exploitation of
vulnerable populations and will reconvene to dis-
cuss the development of these standards.12,13
Individuals who survive cancer are not specifi-
cally legally prohibited from adoption; however,
patientswith cancer havedocumenteddifficulty in
adopting.14 When evaluating this issue formally,
we found that adoption services were not up to
date on the latest survivorship data. Thus, percep-
tion rather than legal issuesmay remain the great-
est barrier to adoption for this cohort.
Although fertility preservationprocedureswerenot
as commonly identified as being associated with
cultural barriers over third-party assisted repro-
duction options, we identified unique regional in-
stances. Specifically, the Banco de Seˆmen do Rio
de Janeiro stated that the lack of compensation for
sperm donors is a huge barrier to providing this
service to patients. Cultural customs play a signif-
icant role in the regulation of third-party ARTs,
whichareexplicitly observed in twoof the surveyed
countries, Egypt and Tunisia. Both countries com-
pletely outlaw egg, sperm, and embryo donation.
In addition, Tunisian representatives from theART
center at the Aziza Othmana Hospital of Tunis
cited the perceived loss of virginity as a great factor
in female patients’ hesitance to undergo trans-
vaginal procedures, such as oocyte retrieval, a
procedure required for oocyte cryopreservation.
Such cultural barriers likely will be more challeng-
ing to surmount because of the ingrainedquality of
these conventions. Fortunately, the repurposing
of a technique abandoned in the 1980s for this
new indication, the perurethral transvesical route
whereoocytesare retrieved through thebladder,15
allows oncofertility to advance as a field and im-
proves access for patients in a world where these
barriers are the current reality and may take de-
cades to overcome.
In conclusion, tremendous differences in cultural
norms; legislation; and accessibility of surrogacy,
adoption, and ART options exist around the world.
Even between neighboring countries, differences
are apparent. These variations point to the need
for consolidating this information; clarification of
the governing laws and attitudes in oncofertility-
practicing countries thereby will help both pro-
viders and patients to provide global understand-
ing about third-party parenting options for patients
who have undergone gonadotoxic cancer treat-
ment and have compromised fertility as a result.
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